Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 54,600 shares, a decline of 46.4% from the February 28th total of 101,800 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 424,200 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ATHE shares. Maxim Group raised their target price on Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Benchmark lowered Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a research note on Monday, February 3rd.

Institutional Trading of Alterity Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in shares of Alterity Therapeutics in the 4th quarter valued at $29,000. Point72 Asset Management L.P. acquired a new position in Alterity Therapeutics in the 4th quarter worth about $108,000. Finally, HB Wealth Management LLC raised its position in Alterity Therapeutics by 34.1% in the fourth quarter. HB Wealth Management LLC now owns 31,883 shares of the company’s stock valued at $110,000 after purchasing an additional 8,100 shares during the last quarter. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Stock Down 1.7 %

Shares of Alterity Therapeutics stock opened at $3.44 on Friday. The firm’s 50 day moving average is $3.90 and its 200 day moving average is $2.53. Alterity Therapeutics has a 1 year low of $1.00 and a 1 year high of $5.87.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.